Suppr超能文献

提高印第安纳州镰状细胞病的可见度:利用多源综合数据确定基线患病率。

Increasing Visibility of Sickle Cell Disease in Indiana: Establishing Baseline Prevalence Using Integrated Data From Multiple Sources.

作者信息

Okolo Amanda I, Jacob Seethal A, Dixon Brian E, Valvi Nimish R, Janson Isaac A, Hardesty Brandon M

机构信息

Indiana Hemophilia and Thrombosis Center, Inc, Indianapolis, IN, USA.

Center for Pediatric and Adolescent Comparative Effectiveness Research, Indiana University, Indianapolis, IN, USA.

出版信息

Public Health Rep. 2024 Mar-Apr;139(2):201-207. doi: 10.1177/00333549231170229. Epub 2023 May 26.

Abstract

OBJECTIVE

The Indiana Sickle Cell Data Collection (IN-SCDC) program aims to provide timely, reliable, and locally relevant information on the sickle cell disease (SCD) population in Indiana to inform public health interventions, research, and policy development. We describe the development of the IN-SCDC program and report the prevalence and geographic distribution of people with SCD in Indiana using an integrated data collection approach.

METHODS

Using multiple integrated data sources and case definitions established by the Centers for Disease Control and Prevention, we classified cases of SCD in Indiana during 2015-2019. We calculated the prevalence and incidence of SCD and described characteristics of people with SCD.

RESULTS

We identified 1695 people living with SCD in Indiana during the study period. The median age of people living with SCD was 21 years, and 1474 (87.0%) were Black or African American. Most (n = 1596, 91%) resided in metropolitan counties. The age-adjusted prevalence of SCD was 24.7 cases per 100 000 people. The prevalence of SCD among Black or African American people was 209.3 per 100 000 people. The incidence was 1 in 2608 live births overall and 1 in 446 live births among Black or African American people. Eighty-six deaths were confirmed in this population during 2015-2019.

CONCLUSIONS

Our results establish a baseline for the IN-SCDC program. Baseline and future surveillance program efforts will help accurately inform standards of care for treatments, identify gaps in coverage and access to care, and provide guidance for legislators and community-based organizations.

摘要

目的

印第安纳镰状细胞病数据收集(IN-SCDC)项目旨在提供有关印第安纳州镰状细胞病(SCD)人群及时、可靠且与当地相关的信息,以为公共卫生干预、研究及政策制定提供依据。我们描述了IN-SCDC项目的发展情况,并采用综合数据收集方法报告了印第安纳州SCD患者的患病率及地理分布。

方法

利用多个综合数据源以及疾病控制与预防中心制定的病例定义,我们对2015 - 2019年印第安纳州的SCD病例进行了分类。我们计算了SCD的患病率和发病率,并描述了SCD患者的特征。

结果

在研究期间我们确定印第安纳州有1695名SCD患者。SCD患者的中位年龄为21岁,其中1474人(87.0%)为黑人或非裔美国人。大多数(n = 1596,91%)居住在大城市县。SCD的年龄调整患病率为每10万人24.7例。黑人或非裔美国人中SCD的患病率为每10万人209.3例。总体活产儿中发病率为1/2608,黑人或非裔美国人活产儿中发病率为1/446。2015 - 2019年期间该人群确认有86例死亡。

结论

我们的结果为IN-SCDC项目建立了基线。基线及未来的监测项目工作将有助于准确告知治疗的护理标准,识别护理覆盖和可及性方面的差距,并为立法者和社区组织提供指导。

相似文献

1
Increasing Visibility of Sickle Cell Disease in Indiana: Establishing Baseline Prevalence Using Integrated Data From Multiple Sources.
Public Health Rep. 2024 Mar-Apr;139(2):201-207. doi: 10.1177/00333549231170229. Epub 2023 May 26.
3
Surveillance for Sickle Cell Disease - Sickle Cell Data Collection Program, Two States, 2004-2018.
MMWR Surveill Summ. 2022 Oct 7;71(9):1-18. doi: 10.15585/mmwr.ss7109a1.
5
Ring the Bell for Sickle Cell: Encouraging Advocacy in an Underserved Community.
Health Promot Pract. 2022 Jul;23(4):560-562. doi: 10.1177/15248399211024169. Epub 2021 Jul 7.
7
Association of Sickle Cell Disease With Racial Disparities and Severe Maternal Morbidities in Black Individuals.
JAMA Pediatr. 2023 Aug 1;177(8):808-817. doi: 10.1001/jamapediatrics.2023.1580.
9
Case Ascertainment of Sickle Cell Disease Using Surveillance or Single Administrative Database Case Definitions.
Public Health Rep. 2024 Mar-Apr;139(2):187-194. doi: 10.1177/00333549231166465. Epub 2023 May 19.
10
Health status and healthcare use in a national sample of children with sickle cell disease.
Am J Prev Med. 2010 Apr;38(4 Suppl):S528-35. doi: 10.1016/j.amepre.2010.01.003.

本文引用的文献

1
Caregiver experiences with accessing sickle cell care and the use of telemedicine.
BMC Health Serv Res. 2022 Feb 22;22(1):239. doi: 10.1186/s12913-022-07627-w.
3
Newborn Screening for SCD in the USA and Canada.
Int J Neonatal Screen. 2018 Nov 26;4(4):36. doi: 10.3390/ijns4040036. eCollection 2018 Dec.
4
Trends in user-initiated health information exchange in the inpatient, outpatient, and emergency settings.
J Am Med Inform Assoc. 2021 Mar 1;28(3):622-627. doi: 10.1093/jamia/ocaa226.
5
Deficient Response to COVID-19 Makes the Case for Evolving the Public Health System.
Am J Prev Med. 2020 Dec;59(6):887-891. doi: 10.1016/j.amepre.2020.07.024. Epub 2020 Aug 26.
6
Adherence to Quality of Care Indicators and Location of Sickle Cell Care Within Indiana.
J Community Health. 2020 Feb;45(1):81-87. doi: 10.1007/s10900-019-00721-x.
7
Improving an Administrative Case Definition for Longitudinal Surveillance of Sickle Cell Disease.
Public Health Rep. 2019 May/Jun;134(3):274-281. doi: 10.1177/0033354919839072. Epub 2019 Apr 10.
9
Pediatric sickle cell disease: past successes and future challenges.
Pediatr Res. 2017 Jan;81(1-2):249-258. doi: 10.1038/pr.2016.204. Epub 2016 Oct 5.
10
Public Health 3.0: Time for an Upgrade.
Am J Public Health. 2016 Apr;106(4):621-2. doi: 10.2105/AJPH.2016.303063.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验